page_title: Takeda Pharmaceutical Company
section_title: History
hierarchical_section_title: Takeda Pharmaceutical Company / History
caption_attribution_description: English: Takeda Midosuji Building, the head office of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Designed by Nikken Sekkei, built in November 1991 by the joint venture of Obayashi Corporation and Takenaka Corporation. Developed by Daiwa Estate (now Takeda Estate), a subsidiary of Takeda. It received an Honourable Mention at the 13th Osaka Urban Scenery and Architectural Design Award in 1993. This photo has been adjusted for perspective distortions with Adobe Photoshop CS. 日本語: 大阪府大阪市中央区道修町四丁目1番1号の武田御堂筋ビル。武田薬品工業本社がある。1991年11月30日竣工。設計は日建設計。施工は大林組、竹中工務店からなる共同企業体。建築主は大和不動産（現:武田薬品不動産、武田薬品の子会社）。第13回大阪まちなみ賞（1993年度）奨励賞を受賞。Adobe Photoshop CSで遠近法を調整した。
context_page_description: The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical and biopharmaceutical company. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo.
  In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.
context_section_description: Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925.
  In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron (leuprorelin) in 1985 and Prevacid (lansoprazole) in 1995.
  One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It was launched in 1999. 
  In February 2005, Takeda acquired San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for US$270 million.
  In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market. In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. On the other hand, Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees. In April 2008, Takeda acquired Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for US$8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary. In May 2008, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.
  In September 2011, Takeda acquired Nycomed for €9.6 billion. 
  In June 2012, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million. On 25 May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million.
  On 26 September 2014, Takeda announced it would team up with BioMotiv to identify and develop new compounds over a five-year period, worth approximately US$25 million. On 30 September 2014, Takeda announced it would expand a collaboration with MacroGenics, valued up to US$1.6 billion. The collaboration focused on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is indicated for lupus and rheumatoid arthritis.
  In 2015, Takeda sold its respiratory drugs business to AstraZeneca for $575 million (about £383 million), which included roflumilast and ciclesonide. On November 20, 2015, the U.S. Food and Drug Administration approved Ixazomib developed by Takeda for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.
  On December 2, 2016, the company spun out its neuroscience research division into Cerevance, a joint venture along with Lightstone Ventures.
  In February 2017, Takeda acquired Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions.
  In January 2018, the company acquired stem cell therapy developer TiGenix for up to €520 million ($632 million).
  In January 2019, Takeda acquired Shire for more than US$50 billion.
  In October 2019, Takeda announced it had sold a portfolio of over-the-counter and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino International for more than $200 million.
  In March 2020, Takeda announced that it has entered into an exclusively agreement to divest a portfolio of non-core products in Latin America to Hypera S.A. for a total value of $825 million.
caption: Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan
exif: {"Image Make": "PENTAX Corporation", "Image Model": "PENTAX *ist DS", "Image Orientation": "Horizontal (normal)", "Image XResolution": "72", "Image YResolution": "72", "Image ResolutionUnit": "Pixels/Inch", "Image Software": "Adobe Photoshop CS2 Macintosh", "Image DateTime": "2006:06:11 00:35:52", "Image YCbCrPositioning": "Co-sited", "Image PrintIM": "[80, 114, 105, 110, 116, 73, 77, 0, 48, 51, 48, 48, 0, 0, 0, 33, 0, 1, 0, 22, ... ]", "Image ExifOffset": "604", "Thumbnail Compression": "JPEG (old-style)", "Thumbnail XResolution": "72", "Thumbnail YResolution": "72", "Thumbnail ResolutionUnit": "Pixels/Inch", "Thumbnail JPEGInterchangeFormat": "1114", "Thumbnail JPEGInterchangeFormatLength": "0", "EXIF ExposureTime": "1/350", "EXIF FNumber": "8", "EXIF ExposureProgram": "Aperture Priority", "EXIF ISOSpeedRatings": "200", "EXIF ExifVersion": "0221", "EXIF DateTimeOriginal": "2006:05:21 15:12:43", "EXIF DateTimeDigitized": "2006:05:21 15:12:43", "EXIF ComponentsConfiguration": "YCbCr", "EXIF ExposureBiasValue": "-1/2", "EXIF MeteringMode": "Pattern", "EXIF Flash": "Flash did not fire, compulsory flash mode", "EXIF FocalLength": "20", "EXIF FlashPixVersion": "0100", "EXIF ColorSpace": "Uncalibrated", "EXIF ExifImageWidth": "1740", "EXIF ExifImageLength": "2260", "EXIF SensingMethod": "One-chip color area", "EXIF FileSource": "Digital Camera", "EXIF SceneType": "Directly Photographed", "EXIF CustomRendered": "Normal", "EXIF ExposureMode": "Auto Bracket", "EXIF WhiteBalance": "Auto", "EXIF FocalLengthIn35mmFilm": "30", "EXIF SceneCaptureType": "Standard", "EXIF Contrast": "Normal", "EXIF Saturation": "Normal", "EXIF Sharpness": "Normal", "EXIF SubjectDistanceRange": "3"}